Brokerages Expect Check Cap Ltd (NASDAQ:CHEK) to Announce ($0.43) Earnings Per Share

Check Cap Ltd (NASDAQ:CHEK) has been assigned a consensus broker rating score of 1.50 (Buy) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company.

Brokers have set a 12 month consensus target price of $10.00 for the company and are forecasting that the company will post ($0.43) EPS for the current quarter, according to Zacks. Zacks has also given Check Cap an industry rank of 40 out of 255 based on the ratings given to related companies.

Separately, HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of Check Cap in a report on Wednesday, July 10th.

Shares of NASDAQ:CHEK opened at $1.74 on Tuesday. The company has a fifty day moving average of $1.91 and a 200-day moving average of $2.18. Check Cap has a 52-week low of $1.55 and a 52-week high of $4.20.

Check Cap (NASDAQ:CHEK) last announced its quarterly earnings results on Wednesday, August 7th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.05. On average, sell-side analysts anticipate that Check Cap will post -1.66 EPS for the current year.

A hedge fund recently raised its stake in Check Cap stock. Renaissance Technologies LLC boosted its stake in Check Cap Ltd (NASDAQ:CHEK) by 24.3% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 307,468 shares of the medical research company’s stock after purchasing an additional 60,026 shares during the period. Renaissance Technologies LLC owned about 19.16% of Check Cap worth $652,000 at the end of the most recent reporting period.

About Check Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient's back for capsule control, tracking, and data recording; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface.

Recommended Story: What is meant by buying and selling pressure?

Get a free copy of the Zacks research report on Check Cap (CHEK)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with's FREE daily email newsletter.